Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Staar Surgical Co
STAA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$21.97
0.36
1.67%
Ult. Agg.: Oct 22, 9:46 AM
$21.46
-0.15
-0.69%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 tra 13 giorni da adesso in mer nov 4th, dopo la chiusura del mercato
Staar Surgical Financials
Staar Surgical (STAA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Staar Surgical Q2 EPS $0.16 Beats $0.15 Estimate, Sales $93.535M Beat $90.589M Estimate
Staar Surgical (NASDAQ:STAA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the
Benzinga Newsdesk
Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions
STAAR Surgical expects preliminary Q2 2026 net sales to top $90 million, driven by strong Americas growth and an inventory rebound in China.
Vandana Singh
PRO
STAAR Surgical Reports Q2 Preliminary Net Sales To Be Over $90M
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second
Benzinga Newsdesk
PRO
Staar Surgical Q1 EPS $0.10 Beats $(0.06) Estimate, Sales $93.522M Beat $75.509M Estimate
Staar Surgical (NASDAQ:STAA) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.06) by 266.67 percent. This is a 115.63 percent increase over losses of $(0.64) per share from
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Staar Surgical Q1 Revenue expected to be more than $90.000M vs $70.325M Est
Staar Surgical (NASDAQ:STAA) Q1 Revenue expected to be more than $90.000M vs $70.325M Est
Benzinga Newsdesk
